PMV Pharmaceuticals, Inc. obtained feedback that continues to support its strategy for submitting a New Drug Application (NDA) for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer with a TP53 Y220C mutation.
Public source
Publisher name
Public post
Today we announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt. The updated data showed an…
Company
PMV Pharmaceuticals, Inc.
Harnessing the power of p53 to treat cancer
- Location
- Princeton, US
- Company size
- 51–200 employees
About PMV Pharmaceuticals, Inc.
At PMV, we believe that by specifically targeting each mutant p53 we can fundamentally disrupt the course of cancer. Our research and development efforts are dedicated to selectively targeting mutant p53, providing unique therapies for any patient whose tumor harbors these gene mutations.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
IDEAYA Biosciences
IDEAYA Biosciences announced a successful FDA Type C meeting for IDE849, DLL3 TOP1 ADC on Phase 3 Registrational Trial Design for potential accelerated and full approval in extensive stage small cell lung cancer
Legal & Regulatory
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new treatment in frontline myelofibrosis based on results from the Phase 3 SENTRY trial presented at ASCO, EHA, and published in a peer-reviewed journal.
Legal & Regulatory
OS Therapies
OS Therapies continues preparations for regulatory submissions and the confirmatory Phase 3 Metastatic Osteosarcoma Program trial.
Legal & Regulatory
Pancreatic Cancer Action Network
Pancreatic Cancer Action Network reported that the U.S. Food and Drug Administration granted approval for a new drug targeting mutations driving more than 90% of pancreatic cancer cases, RASONQUE™ (daraxonrasib).
Legal & Regulatory
SOTIO Biotech